BioMerieux (FRA:EYWN) Other Long Term Assets: €217 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:EYWN BioMerieux SA FRA:EYWN
82 GF Score
Price €72.75
GF Value €108.68
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is BioMerieux Other Long Term Assets?

BioMerieux FRA:EYWN -0.95% 82 Other Long Term Assets is €217 Mil as of Jun. 2026. GuruFocus rates FRA:EYWN with a GF Score™ of 82/100 and a GF Value™ of €108.68 (Significantly Undervalued). The stock has 3 warning signs investors should review.

BioMerieux's other long-term assets for the quarter that ended in Jun. 2026 was €217 Mil.

BioMerieux's quarterly other long-term assets declined from Jun. 2025 (€358 Mil) to Dec. 2025 (€248 Mil) but then stayed the same from Dec. 2025 (€248 Mil) to Jun. 2026 (€217 Mil).

BioMerieux's annual other long-term assets increased from Dec. 2023 (€320 Mil) to Dec. 2024 (€351 Mil) but then declined from Dec. 2024 (€351 Mil) to Dec. 2025 (€248 Mil).

BioMerieux Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for BioMerieux's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioMerieux Other Long Term Assets Chart

BioMerieux Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 106.50 162.60 320.40 350.80 247.80

BioMerieux Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 285.70 350.80 357.80 247.80 217.30
FRA:EYWN
82GF Score
BioMerieux SA FRA:EYWN
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioMerieux Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of €217 Mil mean?
BioMerieux (FRA:EYWN) has a Other Long Term Assets of €217 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on BioMerieux and its competitors.
Is BioMerieux's Other Long Term Assets too high?
BioMerieux's current Other Long Term Assets is €217 Mil. Overall, BioMerieux has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMerieux's Other Long Term Assets compare to TMO and DHR?
BioMerieux's Other Long Term Assets of €217 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Medical Diagnostics & Research company?
A good Other Long Term Assets depends on the Medical Diagnostics & Research industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on BioMerieux and its competitors. BioMerieux's current Other Long Term Assets is €217 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMerieux stock overvalued right now?
Based on GuruFocus' analysis, BioMerieux (FRA:EYWN) is currently considered Significantly Undervalued. The stock's GF Value™ is €108.68, compared to a current price of €72.75 — trading 33.1% below its estimated fair value. The current Other Long Term Assets is €217 Mil. BioMerieux's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For BioMerieux (FRA:EYWN), the current Other Long Term Assets is €217 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioMerieux (FRA:EYWN) Overvalued in 2026?

Based on GuruFocus' analysis, BioMerieux stock appears to be undervalued. The current stock price of €72.75 is trading 33.1% below its estimated GF Value™ of €108.68. GuruFocus considers BioMerieux to be Significantly Undervalued.

Key valuation signals for FRA:EYWN:

  • Other Long Term Assets: €217 Mil
  • GF Value™: €108.68 vs. price of €72.75 (33.1% below fair value)
  • GF Score™: 82/100 with 3 warning signs

No single metric tells the full story. See the FRA:EYWN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioMerieux Business Description

Address Marcy l’Etoile, Lyon, FRA, 69280
BioMérieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (42% of 2024 sales), microbiology (33%), immunoassays (10%), and industrial applications (about 15%). The Americas account for the largest portion of the firm's revenue (40%), followed by Asia-Pacific (27%) and Europe, the Middle East, and Africa (27%). BioMérieux is headquartered in Marcy-l'Étoile, France.
82GF Score

Get the complete analysis for FRA:EYWN

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€72.75
Price
€108.68
GF Value